Navigation Links
IFRS Information - First Half of 2007
Date:9/13/2007

BASINGSTOKE, England, September 13 /PRNewswire-FirstCall/ -- In order to meet its obligations under the Listing Rules of the Financial Services Authority, Shire plc ("Shire") (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) is publishing today its interim results for the six months ended 30 June 2007 in accordance with International Financial Reporting Standards (IFRS).

It should be noted that on 26 July 2007, Shire announced its results in respect of the same period in accordance with US GAAP.

Notes to Editors

Shire plc

Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

Should any shareholder wish to receive a hard copy of the Interim Report, please email Investor Relations on investorrelations@shire.com.

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties ma
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Imaging and Analysis of DIGE Product Information Sheet, Rev B
2. Study affirms information technology-productivity link
3. TrafficCast integrates new information source
4. Rote education fails the Information Age
5. Weather information companies launch data product
6. TeraMedica launches information manager
7. Global information firm reaches diverse markets
8. Preparing for avian flu with information technology
9. Businesses cant hide personal information losses, theft
10. S.C. Johnson lands in No. 2 spot in Information Week 500 list
11. Crate and Barrel deploys Firstlogics Information Quality Suite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
(Date:2/26/2015)... Feb. 26, 2015   Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... President and Chief Executive Officer of Regulus, will present ... th Annual Healthcare Conference on Wednesday, March 4, ... held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)...  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the ... hair rejuvenation, has announced that it has selected ... investor relations and strategic communications. ... diversification strategies – and we need to communicate ... Ali Kharazmi CEO of NuGene when announcing this ...
(Date:2/26/2015)... Innovation is more urgent than ever. Radical ... the world and transforming global markets in industry ... health care, disruption is constantly underway. , As ... shake the foundations of established business models, large-scale ... survive the next wave of mega-change. , This ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2
... (Nasdaq: OREX ), a biopharmaceutical company focused on ... third quarter of 2011. For the three months ended September ... or $0.10 per share, as compared to a net loss ... quarter of 2010. As of September 30, 2011, Orexigen had ...
... an open-source, web-based platform for data-intensive biomedical and ... "cloud computing" resource. A team of researchers including ... molecular biology at Penn State University; Kateryna Makova, ... and James Taylor from Emory University, developed the ...
... plastics could be produced using an intricate chemical process ... 80,000 times smaller than a hair,s breadth ... could give materials exceptional versatility. By weaving threads ... at the University of Edinburgh have created the building ...
Cached Biology Technology:Orexigen® Therapeutics Reports Third Quarter Financial Results 2Orexigen® Therapeutics Reports Third Quarter Financial Results 3Orexigen® Therapeutics Reports Third Quarter Financial Results 4Orexigen® Therapeutics Reports Third Quarter Financial Results 5Galaxy DNA-analysis software is now available 'in the cloud' 2Galaxy DNA-analysis software is now available 'in the cloud' 3Tying atomic threads in knots may produce material benefits 2
(Date:2/24/2015)... , Feb. 24, 2015 Research and ... the addition of the "Global 2D Gesture ... The analysts forecast the Global ... CAGR of 32.12% over the period 2014-2019 ... in non-traditional sectors is one of the major ...
(Date:2/19/2015)... DUBLIN , Feb .19, 2015 Research ... announced the addition of the "Military Electro-Optical ... by Sensor Technology, by Platform - Forecast to ... The military electro-optical/infrared systems market is expected ... a CAGR of 7.71%. This report ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3ACT Genomics Raises $8 Million in its First Private Funding Round 2
... the mechanical strength of cancer cell mucus layers provides ... suggests why some cancer cells are more resistant to ... of engineering at Northeastern University, Boston, Mass. ... protect against infection. Cancer cells, however, produce far more ...
... March, 2011 A recent special edition of the journal ... of the British Mycological Society, features a total of 76 ... cell biology movies ever published. The movies were produced by ... is a renowned researcher in the field of fungal cell ...
... A Purdue University scientist,s nanopolymer would make it easier ... of a widely used class of cancer inhibitors. ... chemistry and a member of the Purdue Center for ... can be used to determine whether cancer drugs have ...
Cached Biology News:Breaking the mucus barrier unveils cancer cell secrets 2Purdue startup hopes to change the way we test cancer drugs 2
...
... The organic acid analysis ... of six organic salts; molecular ... 294. This standard is provided ... HPX-87H column and the organic ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
Biology Products: